Renny Clark

Medtech News: 2025 if off to an M&A roar... Boston Scientific announces its intension to acquire Carlsbad, CA Bolt Medical , developer of an intravascular lithotripsy (IVL) advanced laser-based platform for treating coronary and peripheral artery disease, for an initial $443M, with an additional future regulatory milestone kicker for $221M. https://lnkd.in/gRHmGuf2 #acquisition #medtech #medicaldevice #IVL #lithotripsy #laser

14

Jason Gardner, Flagship CEO-Partner & CEO of #FlagshipFounded Ampersand Biomedicines discusses what drew him to Flagship and its ecosystem, leveraging data and AI with Ampersand's AND-Platform™, and why paranoid optimism is a key part of the culture at Flagship in this #BusinessofBiotech episode with Matthew Pillar. ⬇

22

How do you empower your people to establish quality as a true asset?   In tomorrow's episode Hemish is joined by Sean Smith, VP Quality at KSQ Therapeutics, Inc. Sean started his journey with Amgen before moving to the East Coast and joining the Boston Biotech start-up world! His journey from big pharma to start-ups has benefited him from a technical standpoint, but his willingness to create a purpose-led culture within his team and the industry is what is really impressive.   We talk about the following:   🎤 Transitioning from big pharma to small biotech. 🎤 The mindset shift towards quality as an asset. 🎤 The evolution of quality philosophy. 🎤 The importance of purpose and why in quality leadership. 🎤 Developing individuals and instilling purpose in the team. 🎤 Career progression and options for quality leaders. You can watch live on Hemish's LinkedIn tomorrow at 8am EST to learn how to build a purpose-led quality unit that establish your team as a true asset to your organization!🔥  

39

2 Comments

We are thrilled to announce the ADDF's Diagnostics Accelerator has made a landmark $10 million investment in Alamar Biosciences, Inc. to advance precision medicine for Alzheimer’s disease. This funding will support the further development ARGO Dx into an FDA-cleared system to support the development of in vitro diagnostic (IVD) tests. This platform will offer ultrasensitive protein detection and multiplexing for analyzing blood-based biomarkers related to Alzheimer’s and other dementias. Learn more here: https://bit.ly/3C5nAYh.

107

1 Comment

Through our partnership with GRAIL, we're proud to offer eligible members access to Galleri Test–a first-of-its-kind multi-cancer early-detection test. We interviewed GRAIL’s Chief Medical Officer, Jeffrey Venstrom, MD, on the importance of cancer screening and how early detection can impact health outcomes. Read what he had to say in our blog. 🔗: https://lnkd.in/g857rWYy #CancerScreening #PreventiveCare #HealthcareInnovation

39

How do we minimize the number of protocol amendments and increase the operational feasibility of our clinical trials? This article below points out the benefits of using data, conversations and real world data to enhance the feasibility of the protocol design and inclusion/exclusion criteria: 1) Are we being too strict on our criteria in order to "control" for data variability? 2) Do are criteria allow for the intended patient population in the real world (if not, they need to) 3) How realistic is your design in how the study sites actually work? How they see and treat patients? How is your company ensuring the design meets these requirements? https://lnkd.in/gzJzFd-3

4

1 Comment

💡 Simplifying CAR-T workflows will help to break down barriers to patient access Tune into our new episode of the Ori Spotlight Podcast, where Boro Dropulićć, CEO of Vector BioMed, Inc. and Executive Director at Caring Cross, joins Ori CEO Jason C. Foster for a conversation on how decentralized, point-of-care models and open-source workflows are transforming CGT manufacturing. Boro and Jason discuss how low-cost vector production and new manufacturing processes are key to expanding global access to CAR-T therapies, and delve into the role of digital technologies and partnerships in driving down the costs of gene therapies while maintaining GMP quality. Listen now ➡️ https://lnkd.in/eZdT6krq #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

47

3 Comments

Imvax is bringing long-needed innovation to Glioblastoma - a terrible disease without improvement in decades. With a platform technology that promises to transform care across many cancers.

14

Great summary and insight! Starting early is key to developing the critical partnerships needed for a successful launch.

7

Recently I gave a talk at the LEAP conference on how precision medicine and diagnostics are the keys to value based care. In short, my perspective is that for patients, if we don't appropriately target care to their needs, there is no value to patients. If we treat them like the average, instead of using their data to tailor treatment, there is no value. If we don't correctly assess their risk, accurately diagnose their disease, prescribe therapies most likely to work, prevent adverse events, there is no value. But from a hospital system perspective, apparently that's not how we get "value". From STAT, the CEO of MassGeneral Brigham"...we have been aggressively pushing value-based care now for a number of years. Value-based care is one of the foundational goals and system priorities that we have. Value-based care, in its essence, means to take those patients who do not require the care in the academic medical centers and move them into a community setting, which is lower-cost, or an ambulatory site, which is even lower-cost than our academic medical centers." That definition of value based care means pushing patients to lower-cost centers, which reduces operational costs to a hospital system like MGB. But does that provide value to the patient? #valuebasedcare #precisionmedicine #diagnostics https://lnkd.in/eWUSXf_B

19

1 Comment

There is a lot of advancement happening globally using the tools of AI. In drug discovery, using AI in an appropriate way to build a pipeline of effective solutions for patient health - therapeutics and diagnostics - that is where the rubber meets the road. Pipeline is key.

13

Fabulous to be on the investor panel for Mintz’s Life Sciences Pitch Event today, on yet another glorious fall day in Boston. ☀️🍁 Key feedback shared by our panel: 🔹 Ensure your target market is clear - especially when the population for your relevant indication is highly heterogenous 🔹 Share your current assumptions about how your product may be used (e.g., chronically vs. episodically) and open questions 🔹 If you're exploring a range of commercial use cases, share how you anticipate prioritizing across them over time 🔹 If your GTM strategy requires you to displace heavily entrenched solutions and/or processes, share how you will enable these transitions 🔹 Note the specific set of milestones to be achieved with investment 🔹 Always include target timelines and potential paths to exit Thank you to the incredible lineup of entrepreneurs who pitched today, and please stay in touch! Thank you to Dean Farmer and Charlie C. for facilitating today's event. Thank you to panelists David Fogel, CPA, Ben Littauer (he/him), Molly Hoult, and Richard Wagner for your contributions. Great to meet you, and thank you for all of your help, Emily (Krasowski) Yanachkov and Diana Malkin. #lifesciences #pitchevent #investor #panel #boston

86

4 Comments

The pandemic was a challenging period for all. But it also offered us opportunities! The concept of Jupiter is a great example. Jupiter Bioventures, a product of virtual brainstorming with friends (Ned David, Ned Sharpless and Steve Tregay) to enable Mayo Clinic’s insatiable desire to create the next generation of Cures, is now a powerhouse of drug development that has attracted value-aligned investors and academic partners to join forces in the best interest of patients everywhere…. Congratulations Jupiter team! May the patients win….. Norman Sharpless Nathaniel David Steve Tregay Nirdesh K Gupta, PhD Steven VanNurden Peter Noseworthy, MD Vijay Shah Heidi Dieter Andy Danielsen Mayo Clinic Ventures James Rogers Clark Otley Olayemi (Yemi) Sokumbi, M.D. Pankaj Jay Pasricha Waleed Brinjikji Janani Reisenauer Justin Butler Geoff Johnson, MD, PhD Melissa Noel, MBA, MSE, Johannes Fruehauf, Owen Garrick, MD, Jeanette Caban Cheryl Willman, M.D. #venture, #biopharma, #capital, #venturecapital #accelerator, #drug #drugdevelopment, #development, #technology, #commercialization, #technologytransfer, #research, #clinicaltrial, #patient, #cure, #transform, #venturestudio, #disease, #cancer

76

8 Comments